Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients. Learn more at: http://bit.ly/NAFTA-Obstacles-blog
Issues